A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Lilly

Status and phase

Not yet enrolling

Phase 4

Conditions

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Treatments

Drug: Pirtobrutinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT06876662

2024-517760-29-00 (EU Trial (CTIS) Number)

J2N-MC-JZ01 (Other Identifier)

27289

Details and patient eligibility

About

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Enrollment

279 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Are currently enrolled and active in the originator study, 18001. A participant is considered active in the study if they are:
- receiving study intervention
- in the short-term follow-up period, or
- in the long-term follow-up period.

Exclusion criteria

Were a participant in the Phase 1b cohort of Study 18001.
Are pregnant or intend to become pregnant during the study or within 30 days of last dose of study treatment or intend to breastfeed during the study or within 1 week of the last dose of study treatment.